treosulfan

immunosuppressant; RN given refers to (S-(R*,R*))-isomer

Also Known As:

L-dihydroxybusulfan; L-threitol-1,4-bismethanesulfonate; NSC 39069; treosulfan, ((R*,R*)-(+-))-isomer; treosulfan, (R*,R*)-isomer; treosulfan, (R*,S*)-isomer; treosulfan, (R-(R*,R*))-isomer; (S-(R*,R*))- 1,2,3,4-butanetetrol, 1,4-dimethanesulfonate

Networked: 210 relevant articles (40 outcomes, 55 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Baumgart, Joachim: 15 articles (01/2022 - 02/2003)
2.	Nagler, Arnon: 10 articles (01/2022 - 12/2007)
3.	Ciceri, Fabio: 8 articles (01/2022 - 08/2015)
4.	Casper, Jochen: 7 articles (10/2022 - 01/2009)
5.	Hilgendorf, Inken: 7 articles (10/2022 - 07/2010)
6.	Locatelli, Franco: 7 articles (03/2022 - 07/2012)
7.	Pichlmeier, Uwe: 7 articles (01/2022 - 02/2003)
8.	Kröger, Nicolaus: 7 articles (11/2021 - 07/2010)
9.	Shimoni, Avichai: 7 articles (11/2021 - 12/2007)
10.	Główka, Franciszek K: 7 articles (10/2019 - 01/2013)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2015 - "Treosulfan is at least partially effective by triggering apoptosis of tumor cells. " 01/01/1998 - "For a clinical and pharmacology study, patients with advanced, refractory, or resistant solid tumors were treated with a single-dose intravenous 30-min infusion of 8 or 10 g/m2 treosulfan. " 05/10/2023 - "We analyzed the safety and efficacy data, as well as the treosulfan pharmacokinetics, correlating them with tumor responses. " 01/01/2015 - "The cytotoxic drug Treosulfan is clinically used for the treatment of malignancy. " 05/01/2009 - "Seventy-two hours after injection of treosulfan the ADC values in the viable parts of the tumor of mice treated with the high dose of treosulfan further increased and the tumor volume in the high-dose group was now significantly lower than in the low-dose group. "
2.	beta-Thalassemia (Cooley's Anemia) 01/01/2013 - "Improved clinical outcomes of high risk β thalassemia major patients undergoing a HLA matched related allogeneic stem cell transplant with a treosulfan based conditioning regimen and peripheral blood stem cell grafts." 01/01/2018 - "Second Hematopoietic Stem Cell Transplant for Thalassemia Major: Improved Clinical Outcomes with a Treosulfan-Based Conditioning Regimen." 10/17/2023 - "We evaluated the dose-exposure-response relationship of treosulfan and its active metabolite S, S-EBDM, in a uniform cohort of patients with β-thalassemia major to identify whether therapeutic drug monitoring (TDM) and dose adjustment of treosulfan is feasible. " 01/01/2018 - "Pharmacokinetics and Pharmacodynamics of Treosulfan in Patients With Thalassemia Major Undergoing Allogeneic Hematopoietic Stem Cell Transplantation." 07/12/2012 - "Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan."
3.	Leukemia 01/01/1980 - "The probability of developing acute leukemia in this study was not significantly correlated to the total cumulative dosage of Treosulfan. " 01/01/2018 - "However, there was better survival with treosulfan-based conditioning in advanced leukemia. " 07/15/2017 - "To investigate the role of treosulfan-based conditioning, the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party performed a registry analysis of 520 adult patients with AML who received treosulfan-based conditioning and underwent HCT between 2000 and 2012, including 225 patients in first complete remission, 107 in second or later complete remission, and 188 with active/advanced disease 188 (88 with primary refractory disease). " 01/01/2019 - "The FLAMSA-reduced intensity conditioning protocol (total body irradiation or treosulfan-based) has been described as an effective approach in patients with refractory leukemia undergoing allogeneic hematopoietic cell transplantation. " 01/01/2018 - "Treosulfan-based conditioning is more similar to myeloablative than to reduced-intensity conditioning but can be administered safely in older patients, with lower rates of graft-versus-host disease and possibly better outcomes in patients with active leukemia."
4.	Melanoma (Melanoma, Malignant) 01/01/2003 - "Treosulfan in the treatment of metastatic melanoma: from chemosensitivity testing to clinical trials." 02/01/2003 - "In conclusion, intravenous treosulfan treatment does not induce objective response rates when used as a second-line treatment of metastatic malignant melanoma." 01/01/2003 - "A total of 31 patients with stage IV melanoma were included and treated second-line with 8 g/m2 i.v. treosulfan. " 04/01/1999 - "Three cell lines and eight of the 10 tested tumour cells isolated from melanoma metasteses showed tumour growth inhibition >50% after incubation with treosulfan. " 02/01/2003 - "The purpose of this multicentre phase II trial was to evaluate time to progression, survival time, rate of objective tumour response and toxicity of second-line intravenous treosulfan chemotherapy in stage IV melanoma patients. "
5.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 12/01/2020 - "Sequential treatment with FLAG-IDA/treosulfan conditioning regimen for patients with active acute myeloid leukemia." 09/01/2005 - "We successfully performed two allogeneic hematopoietic stem cell transplantations from matched unrelated donors without the use of blood-product support after treosulfan-based conditioning in two women with acute myeloid leukemia who were Jehovah's witnesses and refused transfusions of blood products." 01/01/2018 - "This multicenter study evaluated a treosulfan-based regimen in children and young adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell transplant (HCT). " 05/10/2023 - "In our previous work, we showed promising efficacy and safety results for treosulfan (14 g/m2) and melphalan (200 mg/m2) (TreoMel) in acute myeloid leukemia (AML) patients receiving ASCT. " 01/01/2019 - "Comparison of FLAMSA-based reduced intensity conditioning with treosulfan/fludarabine conditioning for patients with acute myeloid leukemia: an ALWP/EBMT analysis."

Related Drugs and Biologics

1.	fludarabine
2.	Gemcitabine
3.	Thiotepa (Triethylenethiophosphoramide)
4.	Cisplatin (Platino)
5.	Busulfan (Busulfex)
6.	Alkylating Agents
7.	Adenosine Triphosphate (ATP)
8.	Cyclophosphamide (Cytoxan)
9.	Doxorubicin (Adriamycin)
10.	Fluorouracil (Carac)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Hematopoietic Stem Cell Transplantation
3.	Transplantation
4.	Stem Cell Transplantation
5.	Therapeutics